1-8 of 8
Guillaume Cartron
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

“Don't keep me waiting”: estimating the impact of reduced vein-to-vein time on lifetime US 3L+ LBCL patient outcomes

Sachin Vadgama, Marcelo C. Pasquini, Richard T. Maziarz, Zhen-Huan Hu, Markqayne Ray, Harry Smith, Ash Bullement, Mark Edmondson-Jones, Will Sullivan, Guillaume Cartron
Journal: Blood Advances
Blood Adv (2024) 8 (13): 3519–3527.
https://doi.org/10.1182/bloodadvances.2023012240
Published: 2024
Includes: Supplemental data
Journal Articles

Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study)

Samuel Vic, Jean-Baptiste Thibert, Emmanuel Bachy, Guillaume Cartron, Thomas Gastinne, Franck Morschhauser, Fabien Le Bras, Kamal Bouabdallah, Fabien Despas, Jacques-Olivier Bay, Marie-Thérèse Rubio, Mohamad Mohty, Olivier Casasnovas, Sylvain Choquet, Cristina Castilla-Llorente, Stéphanie Guidez, Michaël Loschi, Blandine Guffroy, Sylvain Carras, Laurianne Drieu La Rochelle, Mathilde Guillet, Roch Houot
Journal: Blood Advances
Blood Adv (2024) 8 (6): 1573–1585.
https://doi.org/10.1182/bloodadvances.2023011727
Published: 2024
Includes: Supplemental data
Journal Articles

Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry

Clinical Trials & Observations
Jean Lemoine, Emmanuel Bachy, Guillaume Cartron, David Beauvais, Thomas Gastinne, Roberta Di Blasi, Marie-Thérèse Rubio, Stéphanie Guidez, Mohamad Mohty, Rene-Olivier Casasnovas, Magalie Joris, Cristina Castilla-Llorente, Corinne Haioun, Olivier Hermine, Michael Loschi, Sylvain Carras, Pierre Bories, Tom Fradon, Charles Herbaux, Pierre Sesques, Steven Le Gouill, Franck Morschhauser, Catherine Thieblemont, Roch Houot
Journal: Blood Advances
Blood Adv (2023) 7 (21): 6589–6598.
https://doi.org/10.1182/bloodadvances.2023010624
Published: 2023
Includes: Supplemental data
Journal Articles

A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial

Clinical Trials & Observations
Anne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, Lydia Campos, Michel Ticchioni, Marie-Sarah Dilhuydy, Stephane Morisset, Valérie Rouille, Béatrice Mahé, Kamel Laribi, Bruno Villemagne, Emmanuelle Ferrant, Olivier Tournilhac, Alain Delmer, Lysiane Molina, Véronique Leblond, Cécile Tomowiak, Sophie de Guibert, Frederique Orsini-Piocelle, Anne Banos, Philippe Carassou, Guillaume Cartron, Luc Mathieu Fornecker, Loic Ysebaert, Caroline Dartigeas, Margot Truchan-Graczyk, Jean-Pierre Vilque, Thérèse Aurran Schleinitz, Florence Cymbalista, Stéphane Leprêtre, Vincent Lévy, Florence Nguyen-Khac, Pierre Feugier
Journal: Blood Advances
Blood Adv (2023) 7 (15): 3936–3945.
https://doi.org/10.1182/bloodadvances.2022009594
Published: 2023
Includes: Supplemental data
Journal Articles

Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group

Yassine Al Tabaa, Rene Oliver Casasnovas, Clio Baillet, Emmanuel Bachy, Emmanuelle Nicolas-Virelizier, Jean Marc Schiano De colella, Clement Bailly, Salim Kanoun, Stéphanie Guidez, Emmanuel Gyan, Remy Gressin, Nadine Morineau, Loic Ysebaert, Steven Le Gouill, Herve Tilly, Roch Houot, F. Morschhauser, Guillaume Cartron, Charles Herbaux
Journal: Blood Advances
Blood Adv (2023) 7 (14): 3735–3738.
https://doi.org/10.1182/bloodadvances.2023009911
Published: 2023
Includes: Supplemental data
Journal Articles

G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor–mediated cell death

Eva De Smedt, Julie Devin, Catharina Muylaert, Nicolas Robert, Guilhem Requirand, Philip Vlummens, Laure Vincent, Guillaume Cartron, Ken Maes, Jerome Moreaux, Elke De Bruyne
Journal: Blood Advances
Blood Adv (2021) 5 (9): 2325–2338.
https://doi.org/10.1182/bloodadvances.2020003217
Published: 2021
Includes: Supplemental data
Journal Articles

Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma

Clinical Trials & Observations
François Lemonnier, Violaine Safar, Asma Beldi-Ferchiou, Anne-Ségolène Cottereau, Emmanuel Bachy, Guillaume Cartron, Virginie Fataccioli, Laura Pelletier, Cyrielle Robe, Audrey Letourneau, Edoardo Missiaglia, Slim Fourati, Marie-Pierre Moles-Moreau, Alain Delmer, Reda Bouabdallah, Laurent Voillat, Stéphanie Becker, Céline Bossard, Marie Parrens, Olivier Casasnovas, Victoria Cacheux, Caroline Régny, Vincent Camus, Marie-Hélène Delfau-Larue, Michel Meignan, Laurence de Leval, Philippe Gaulard, Corinne Haioun
Journal: Blood Advances
Blood Adv (2021) 5 (2): 539–548.
https://doi.org/10.1182/bloodadvances.2020003081
Published: 2021
Includes: Supplemental data
Journal Articles

Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study

Clinical Trials & Observations
Marie-Helene Delfau-Larue, Marie-Laure Boulland, Asma Beldi-Ferchiou, Pierre Feugier, Hervé Maisonneuve, Rene-Olivier Casasnovas, François Lemonnier, Gian Matteo Pica, Roch Houot, Loic Ysebaert, Hervé Tilly, Jean-Claude Eisenmann, Steven Le Gouill, Vincent Ribrag, Pascal Godmer, Sylvie Glaisner, Guillaume Cartron, Luc Xerri, Gilles André Salles, Thierry Fest, Franck Morschhauser
Journal: Blood Advances
Blood Adv (2020) 4 (14): 3217–3223.
https://doi.org/10.1182/bloodadvances.2020001955
Published: 2020
Includes: Supplemental data